{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:41:08Z","timestamp":1707525668769},"reference-count":8,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,20]]},"DOI":"10.7759\/cureus.52636","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T00:35:40Z","timestamp":1705797340000},"source":"Crossref","is-referenced-by-count":0,"title":["Pembrolizumab-Induced Colitis and Diarrhea in the Treatment of Sporadic Colorectal Cancer: A Case Report"],"prefix":"10.7759","author":[{"given":"Rejath","family":"Jose","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasveen","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theophany","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Ehrlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Marcelin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand Y","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SM, et al.. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022, 29:3044-60. 10.3390\/curroncol29050247","journal-title":"Curr Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/med.21765","article-title":"Understanding the tumor microenvironment for effective immunotherapy","volume":"41","author":"Rad HS","year":"2021","unstructured":"Rad HS, Monkman J, Warkiani ME, Ladwa R, O'Byrne K, Rezaei N, Kulasinghe A. Understanding the tumor microenvironment for effective immunotherapy. Med Res Rev. 2021, 41:1474-98. 10.1002\/med.21765","journal-title":"Med Res Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0241-1","article-title":"Biomarker-guided therapy for colorectal cancer: strength in complexity","volume":"17","author":"Sveen A","year":"2020","unstructured":"Sveen A, Kopetz S, Lothe RA. Biomarker-guided therapy for colorectal cancer: strength in complexity. Nat Rev Clin Oncol. 2020, 17:11-32. 10.1038\/s41571-019-0241-1","journal-title":"Nat Rev Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-1885","article-title":"Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer","volume":"74","author":"Steinert G","year":"2014","unstructured":"Steinert G, Sch\u00f6lch S, Niemietz T, et al.. Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer. Cancer Res. 2014, 74:1694-704. 10.1158\/0008-5472.CAN-13-1885","journal-title":"Cancer Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9 T","year":"2020","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW, et al.. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020, 383:2207-18. 10.1056\/NEJMoa2017699","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v7.i4.405","article-title":"Immune checkpoint inhibitor-induced colitis: a comprehensive review","volume":"7","author":"Som A","year":"2019","unstructured":"Som A, Mandaliya R, Alsaadi D, Farshidpour M, Charabaty A, Malhotra N, Mattar MC. Immune checkpoint inhibitor-induced colitis: a comprehensive review. World J Clin Cases. 2019, 7:405-18. 10.12998\/wjcc.v7.i4.405","journal-title":"World J Clin Cases"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2017.06.007","article-title":"Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable","volume":"44","author":"Prasad V","year":"2017","unstructured":"Prasad V, Kaestner V. Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable. Semin Oncol. 2017, 44:132-5. 10.1053\/j.seminoncol.2017.06.007","journal-title":"Semin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4291\/wjgp.v10.i2.17","article-title":"Immune checkpoint inhibitor-induced diarrhea\/colitis: endoscopic and pathologic findings","volume":"10","author":"Nishida T","year":"2019","unstructured":"Nishida T, Iijima H, Adachi S. Immune checkpoint inhibitor-induced diarrhea\/colitis: endoscopic and pathologic findings. World J Gastrointest Pathophysiol. 2019, 10:17-28. 10.4291\/wjgp.v10.i2.17","journal-title":"World J Gastrointest Pathophysiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/199620-pembrolizumab-induced-colitis-and-diarrhea-in-the-treatment-of-sporadic-colorectal-cancer-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:12:55Z","timestamp":1707509575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/199620-pembrolizumab-induced-colitis-and-diarrhea-in-the-treatment-of-sporadic-colorectal-cancer-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,20]]},"references-count":8,"URL":"https:\/\/doi.org\/10.7759\/cureus.52636","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,20]]}}}